Amphastar Pharmaceuticals 将来の成長

Future 基準チェック /26

Amphastar Pharmaceuticals利益と収益がそれぞれ年間6.7%と7.8%増加すると予測されています。EPS は年間増加すると予想されています。自己資本利益率は 3 年後に24.8% 4.5%なると予測されています。

主要情報

6.7%

収益成長率

4.5%

EPS成長率

Pharmaceuticals 収益成長	23.9%
収益成長率	7.8%
将来の株主資本利益率	24.8%
アナリストカバレッジ	Good
最終更新日	22 Nov 2024

今後の成長に関する最新情報

Recent updates

Amphastar: Objectively Undervalued But For Good Reason (Rating Downgrade)

Oct 25

Investors Continue Waiting On Sidelines For Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Sep 15

Amphastar Pharmaceuticals: Shining Star Soon To Fade With Competitive Pressures Looming

Jul 01

Amphastar Pharmaceuticals, Inc.'s (NASDAQ:AMPH) Subdued P/E Might Signal An Opportunity

May 30

Amphastar Pharmaceuticals: Buy When Fear Is Overblown

May 30

Reassessing Amphastar Pharmaceuticals

May 15

Amphastar Pharmaceuticals (NASDAQ:AMPH) Has A Pretty Healthy Balance Sheet

Mar 27

Why Amphastar Pharmaceuticals Is A Strong Buy: Growth, Valuation, And Strategic Acquisitions

Mar 04

Here's Why We Think Amphastar Pharmaceuticals (NASDAQ:AMPH) Might Deserve Your Attention Today

Jan 04

Why Investors Shouldn't Be Surprised By Amphastar Pharmaceuticals, Inc.'s (NASDAQ:AMPH) P/E

Dec 20

Amphastar Pharmaceuticals (NASDAQ:AMPH) Has A Rock Solid Balance Sheet

Dec 03

Amphastar Pharmaceuticals (NASDAQ:AMPH) Ticks All The Boxes When It Comes To Earnings Growth

Sep 18

An Intrinsic Calculation For Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Suggests It's 35% Undervalued

Sep 03

These 4 Measures Indicate That Amphastar Pharmaceuticals (NASDAQ:AMPH) Is Using Debt Safely

Aug 17

Here's Why We Think Amphastar Pharmaceuticals (NASDAQ:AMPH) Is Well Worth Watching

Jun 02

We Think Amphastar Pharmaceuticals (NASDAQ:AMPH) Can Manage Its Debt With Ease

May 11

Amphastar Pharmaceuticals, Inc.'s (NASDAQ:AMPH) Intrinsic Value Is Potentially 51% Above Its Share Price

Mar 02

Is Now The Time To Put Amphastar Pharmaceuticals (NASDAQ:AMPH) On Your Watchlist?

Feb 07

Does Amphastar Pharmaceuticals (NASDAQ:AMPH) Have A Healthy Balance Sheet?

Jan 24

Here's Why Amphastar Pharmaceuticals (NASDAQ:AMPH) Has Caught The Eye Of Investors

Nov 02

Amphastar: A Pharmaceutical Growth Stock

Oct 06

Amphastar wins FDA approval for Epinephrine pre-filled syringes

Aug 16

Amphastar Pharmaceuticals: Compelling Growth Prospects For H2 2022 And Beyond

Aug 08

Do Amphastar Pharmaceuticals' (NASDAQ:AMPH) Earnings Warrant Your Attention?

Jul 24

Amphastar generic vasopressin for increasing blood pressure gets FDA approval

Jul 19

業績と収益の成長予測

NasdaqGS:AMPH - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	873	209	222	286	5
12/31/2025	807	186	202	249	6
12/31/2024	738	174	169	222	6
9/30/2024	724	158	170	208	N/A
6/30/2024	713	167	178	213	N/A
3/31/2024	676	155	161	198	N/A
12/31/2023	644	138	145	184	N/A
9/30/2023	601	135	140	175	N/A
6/30/2023	541	102	100	131	N/A
3/31/2023	519	93	51	79	N/A
12/31/2022	499	91	65	89	N/A
9/30/2022	485	77	90	114	N/A
6/30/2022	477	91	70	97	N/A
3/31/2022	455	81	100	126	N/A
12/31/2021	438	62	71	98	N/A
9/30/2021	413	36	45	74	N/A
6/30/2021	384	10	52	81	N/A
3/31/2021	368	2	45	79	N/A
12/31/2020	350	1	23	57	N/A
9/30/2020	337	7	13	46	N/A
6/30/2020	334	4	-11	25	N/A
3/31/2020	327	52	12	47	N/A
12/31/2019	322	49	0	42	N/A
9/30/2019	329	52	3	46	N/A
6/30/2019	324	53	27	73	N/A
3/31/2019	316	2	-23	26	N/A
12/31/2018	295	-6	-4	38	N/A
9/30/2018	265	-7	-5	38	N/A
6/30/2018	248	-9	N/A	25	N/A
3/31/2018	242	-4	N/A	25	N/A
12/31/2017	240	4	N/A	39	N/A
9/30/2017	243	0	N/A	43	N/A
6/30/2017	250	4	N/A	42	N/A
3/31/2017	252	9	N/A	47	N/A
12/31/2016	255	10	N/A	39	N/A
9/30/2016	269	21	N/A	28	N/A
6/30/2016	268	14	N/A	30	N/A
3/31/2016	254	0	N/A	23	N/A
12/31/2015	252	-3	N/A	11	N/A
9/30/2015	230	-13	N/A	20	N/A
6/30/2015	226	-15	N/A	30	N/A
3/31/2015	221	-10	N/A	28	N/A
12/31/2014	210	-11	N/A	21	N/A
9/30/2014	209	-6	N/A	17	N/A
6/30/2014	209	-1	N/A	4	N/A
3/31/2014	223	8	N/A	24	N/A
12/31/2013	230	12	N/A	31	N/A

アナリストによる今後の成長予測

収入対貯蓄率: AMPHの予測収益成長率 (年間6.7% ) は貯蓄率 ( 2.6% ) を上回っています。

収益対市場: AMPHの収益 ( 6.7% ) US市場 ( 15.2% ) よりも低い成長が予測されています。

高成長収益: AMPHの収益は増加すると予測されていますが、大幅には増加しません。

収益対市場: AMPHの収益 ( 7.8% ) US市場 ( 8.9% ) よりも低い成長が予測されています。

高い収益成長: AMPHの収益 ( 7.8% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: AMPHの自己資本利益率は、3年後には高くなると予測されています ( 24.8 %)

Amphastar Pharmaceuticals 将来の成長

Future 基準チェック /26

主要情報

今後の成長に関する最新情報

Consensus EPS estimates fall by 14%

Price target decreased by 7.3% to US$62.60

Consensus EPS estimates increase by 14%

Consensus EPS estimates increase by 21%

Price target increased by 17% to US$50.50

Consensus EPS estimates increase by 15%

Recent updates

Consensus EPS estimates fall by 14%

CFO, Executive VP of Finance notifies of intention to sell stock

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Amphastar Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 06, 2024

Amphastar: Objectively Undervalued But For Good Reason (Rating Downgrade)

Co-founder exercised options to buy US$5.0m worth of stock.

Investors Continue Waiting On Sidelines For Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Amphastar: Perplexing Pipeline, Lumpy Revenues - I'm On Sidelines

New minor risk - Insider selling

Insider notifies of intention to sell stock

Is Amphastar Pharmaceuticals (NASDAQ:AMPH) Using Too Much Debt?

Lead Independent Director notifies of intention to sell stock

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

CFO, Executive VP of Finance notifies of intention to sell stock

Amphastar Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 07, 2024

Do Amphastar Pharmaceuticals' (NASDAQ:AMPH) Earnings Warrant Your Attention?

Amphastar Pharmaceuticals: Shining Star Soon To Fade With Competitive Pressures Looming

Co-founder exercised options to buy US$4.1m worth of stock.

Amphastar Pharmaceuticals, Inc. Approves the Appointment of Howard Lee as Director

Amphastar Pharmaceuticals, Inc.'s (NASDAQ:AMPH) Subdued P/E Might Signal An Opportunity

Amphastar Pharmaceuticals: Buy When Fear Is Overblown

Amphastar Pharmaceuticals, Inc. Receives FDA Approval for Albuterol Sulfate Inhalation Aerosol

Reassessing Amphastar Pharmaceuticals

First quarter 2024 earnings released: EPS: US$0.90 (vs US$0.54 in 1Q 2023)

Amphastar Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 08, 2024

Amphastar Pharmaceuticals, Inc., Annual General Meeting, Jun 03, 2024

Price target decreased by 7.3% to US$62.60

Amphastar Pharmaceuticals (NASDAQ:AMPH) Has A Pretty Healthy Balance Sheet

Co-founder exercised options and sold US$13m worth of stock

CFO, Executive VP of Finance notifies of intention to sell stock

Insider recently sold US$590k worth of stock

Investor sentiment deteriorates as stock falls 15%

Why Amphastar Pharmaceuticals Is A Strong Buy: Growth, Valuation, And Strategic Acquisitions

Full year 2023 earnings: EPS misses analyst expectations

Amphastar Pharmaceuticals, Inc. Reports Impairment of Long-Lived Assets for the Fourth Quarter Ended December 31, 2023

Amphastar Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 28, 2024

Chairman of the Board notifies of intention to sell stock

Here's Why We Think Amphastar Pharmaceuticals (NASDAQ:AMPH) Might Deserve Your Attention Today

Why Investors Shouldn't Be Surprised By Amphastar Pharmaceuticals, Inc.'s (NASDAQ:AMPH) P/E

Insider exercised options and sold US$343k worth of stock

Amphastar Pharmaceuticals (NASDAQ:AMPH) Has A Rock Solid Balance Sheet

Lead Independent Director recently sold US$263k worth of stock

Lead Independent Director notifies of intention to sell stock

Consensus EPS estimates increase by 14%

Investor sentiment improves as stock rises 22%

Third quarter 2023 earnings released: EPS: US$1.01 (vs US$0.33 in 3Q 2022)

Amphastar Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 08, 2023

Amphastar Pharmaceuticals (NASDAQ:AMPH) Ticks All The Boxes When It Comes To Earnings Growth

CFO, Executive VP of Finance notifies of intention to sell stock

An Intrinsic Calculation For Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Suggests It's 35% Undervalued

Executive VP of Sales notifies of intention to sell stock

Insider recently sold US$730k worth of stock

These 4 Measures Indicate That Amphastar Pharmaceuticals (NASDAQ:AMPH) Is Using Debt Safely

New major risk - Financial position

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Amphastar Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 08, 2023

Consensus EPS estimates increase by 21%

CFO, Executive VP of Finance notifies of intention to sell stock

Investor sentiment improves as stock rises 20%

Price target increased by 17% to US$50.50

Independent Director notifies of intention to sell stock

Here's Why We Think Amphastar Pharmaceuticals (NASDAQ:AMPH) Is Well Worth Watching

Insider recently sold US$316k worth of stock

Investor sentiment improves as stock rises 18%

Lead Independent Director notifies of intention to sell stock

We Think Amphastar Pharmaceuticals (NASDAQ:AMPH) Can Manage Its Debt With Ease

First quarter 2023 earnings released: EPS: US$0.54 (vs US$0.50 in 1Q 2022)

Amphastar Pharmaceuticals, Inc. to Report Q1, 2023 Results on May 09, 2023

Investor sentiment deteriorates as stock falls 15%